| Literature DB >> 34616047 |
Dhanu Gupta1, Oscar P B Wiklander2, André Görgens3,4, Mariana Conceição5, Giulia Corso3, Xiuming Liang3, Yiqi Seow6, Sriram Balusu7,8, Ulrika Feldin3, Beklem Bostancioglu3, Rim Jawad3, Doste R Mamand3,9, Yi Xin Fiona Lee3,10, Justin Hean11, Imre Mäger5, Thomas C Roberts5,12, Manuela Gustafsson3, Dara K Mohammad3,13, Helena Sork3, Alexandra Backlund14, Per Lundin11, Antonin de Fougerolles11, C I Edvard Smith15, Matthew J A Wood5,12, Roosmarijn E Vandenbroucke7,8, Joel Z Nordin16, Samir El-Andaloussi17.
Abstract
Extracellular vesicles (EVs) can be functionalized to display specific protein receptors on their surface. However, surface-display technology typically labels only a small fraction of the EV population. Here, we show that the joint display of two different therapeutically relevant protein receptors on EVs can be optimized by systematically screening EV-loading protein moieties. We used cytokine-binding domains derived from tumour necrosis factor receptor 1 (TNFR1) and interleukin-6 signal transducer (IL-6ST), which can act as decoy receptors for the pro-inflammatory cytokines tumour necrosis factor alpha (TNF-α) and IL-6, respectively. We found that the genetic engineering of EV-producing cells to express oligomerized exosomal sorting domains and the N-terminal fragment of syntenin (a cytosolic adaptor of the single transmembrane domain protein syndecan) increased the display efficiency and inhibitory activity of TNFR1 and IL-6ST and facilitated their joint display on EVs. In mouse models of systemic inflammation, neuroinflammation and intestinal inflammation, EVs displaying the cytokine decoys ameliorated the disease phenotypes with higher efficacy as compared with clinically approved biopharmaceutical agents targeting the TNF-α and IL-6 pathways.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34616047 DOI: 10.1038/s41551-021-00792-z
Source DB: PubMed Journal: Nat Biomed Eng ISSN: 2157-846X Impact factor: 25.671